Sandbox:Balanitis: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{BalanitisV}}
{{Balanitis}}
{{CMG}}; {{AE}}{{VD}}
{{CMG}}; {{AE}}{{VD}}
{{SK}} Balanoposthitis
{{SK}} Balanoposthitis
* '''Please click here to know more about Infectious balanitis'''
* '''Please click here to know more about Penile carcinoma in situ causing Balanitis'''
* '''Please click here to know more about Inflammatory deramtosis causing Balanitis'''
* '''Please click here to know more about Zoon's Balanitis'''
* '''Please click here to know more about Balanitis xerotica obliterans'''
==Overview==
==Overview==
Balanitis is inflammation of glans penis. When balanitis involve foreskin and prepuce it is termed balanoposthitis. Causes of balanitis can be mainly categorized into 1) Infectious 2) Inflammatory dermatoses 3) Penile carcinoma in situ.        
==[[Balanitis overview|Overview]]==
 
Balanitis is inflammation of glans penis. When inflammation involves the foreskin and prepuce, it is termed as balanoposthitis. Based on the etiology, balanitis can be mainly categorized into infectious, inflammatory dermatoses, and penile carcinoma in situ. Patients with balanitis may present with asymptomatic or symptomatic lesions with itch or pain in the genital region. Risk factors, pathogenesis, clinical presentation, diagnosis and management varies depending on etiology.
{| class="wikitable"
|Patient Information 
 
TAGRISSO™ (tuh-GRISS-oh) 
 
(osimertinib) 
 
tablet
|-
|What is the most important information I should know about TAGRISSO?
 
TAGRISSO may cause serious side effects, including:
; •
: lung problems. TAGRISSO may cause lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your doctor right away if you have any new or worsening lung symptoms, including trouble breathing, shortness of breath, cough, or fever.
; •
: heart problems, including heart failure. TAGRISSO may cause heart problems that may lead to death. Your doctor should check your heart function before you start taking TAGRISSO and during treatment. Tell your doctor right away if you have any of the following signs and symptoms of a heart problem: feeling like your heart is pounding or racing, shortness of breath, swelling of your ankles and feet, feeling lightheaded.
See “What are the possible side effects of TAGRISSO?” for more information about side effects.
|-
|What is TAGRISSO?
 
TAGRISSO is a prescription medicine used to treat non-small cell lung cancer (NSCLC). TAGRISSO may be used when your non-small cell lung cancer has spread to other parts of the body and:
; •
: has a certain type of abnormal epidermal growth factor receptor (EGFR) gene, called T790M, and
; •
: you have had previous treatment with an EGFR tyrosine kinase inhibitor medicine and it has stopped working.
Your doctor will perform a test to make sure that TAGRISSO is right for you.
 
It is not known if TAGRISSO is safe and effective in children.
|-
|Before taking TAGRISSO, tell your doctor about all of your medical conditions, including if you:
; •
: have lung or breathing problems
; •
: have heart problems, including a condition called long QTc syndrome
; •
: have problems with your electrolytes, such as sodium, potassium, calcium or magnesium
; •
: are pregnant or plan to become pregnant. TAGRISSO can harm your unborn baby. Tell your doctor right away if you become pregnant during treatment with TAGRISSO or think you may be pregnant.
:; o
:: Females who are able to become pregnant should use an effective birth control during treatment with TAGRISSO and for 6 weeks after the final dose of TAGRISSO.
:; o
:: Males who have female partners that are able to become pregnant should use effective birth control during treatment with TAGRISSO and for 4 months after the final dose of TAGRISSO.
; •
: are breastfeeding or plan to breastfeed. It is not known if TAGRISSO passes into your breast milk. Do not breastfeed during treatment with TAGRISSO and for 2 weeks after your final dose of TAGRISSO. Talk to your doctor about the best way to feed your baby during this time.
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Especially tell your doctor if you take a heart or blood pressure medicine.
|-
|How should I take TAGRISSO?
; •
: Take TAGRISSO exactly as your doctor tells you to take it.
; •
: Your doctor may change your dose, temporarily stop, or permanently stop treatment with TAGRISSO if you have side effects.
; •
: Take TAGRISSO 1 time each day.
; •
: You can take TAGRISSO with or without food.
; •
: If you miss a dose of TAGRISSO, do not make up for the missed dose. Take your next dose at your regular time.
; •
: If you cannot swallow TAGRISSO tablets whole:
:; o
:: place your dose of TAGRISSO in a container that contains 60 mL (2 ounces) of water. Do not use carbonated water or any other liquids.
:; o
:: stir the TAGRISSO tablet and water until the TAGRISSO tablet is in small pieces (the tablet will not completely dissolve). Do not crush, heat, or use ultrasound to prepare the mixture.
:; o
:: drink the TAGRISSO and water mixture right away.
:; o
:: add 120 mL to 240 mL (4 to 8 ounces) of water into the container and drink to make sure that you take your full dose of TAGRISSO.
|-
|What are the possible side effects of TAGRISSO?


TAGRISSO may cause serious side effects, including:
==[[Balanitis historical perspective|Historical Perspective]]==
Balanitis is an ancient disease,The term Balanitis is derived from a Greek term balanos or acorn.


See “What is the most important information I should know about TAGRISSO?”
==[[Balanitis pathophysiology|Pathophysiology]]==


The most common side effects of TAGRISSO are:
==[[Balanitis causes|Causes]]==
; •
: diarrhea
; •
: rash
; •
: dry skin
; •
: changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from nailbed, and shedding of nails
Tell your doctor if you have any side effect that bothers you or that does not go away.


These are not all the possible side effects of TAGRISSO. For more information, ask your doctor or pharmacist.
There is no established classification system for Balantis. Based on the etiologies, Balanitis can be classified into:<ref name="pmid24828553">{{cite journal| author=Edwards SK, Bunker CB, Ziller F, van der Meijden WI| title=2013 European guideline for the management of balanoposthitis. | journal=Int J STD AIDS | year= 2014 | volume= 25 | issue= 9 | pages= 615-26 | pmid=24828553 | doi=10.1177/0956462414533099 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24828553  }}</ref>
 
* [[Infectious balanitis|Infectious]]
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
* [[Inflammatory dermatoses]]
|-
* [[Penile carcinoma in situ]]
|How should I store TAGRISSO?
; •
: Store TAGRISSO at room temperature between 68°F to 77°F (20°C to 25°C).
; •
: Safely throw away medicine that is out of date or that you no longer need.
; •
: Keep TAGRISSO and all medicines out of the reach of children.
|-
|General information about the safe and effective use of TAGRISSO.
; •
: Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use TAGRISSO for a condition for which it was not prescribed. Do not give TAGRISSO to other people, even if they have the same symptoms you have. It may harm them. You can ask your doctor or pharmacist for information about TAGRISSO that is written for a health care professional.
|-
|What are the ingredients in TAGRISSO?
 
Active ingredient: osimertinib
 
Inactive ingredients: mannitol, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, and sodium stearyl fumarate. Tablet coating contains: polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, ferric oxide yellow, ferric oxide red and ferric oxide black.
 
For more information, go to www.TAGRISSO.com or call 1-800-236-9933.
 
Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850
 
©AstraZeneca 2015
|}
;
: This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: August 2016 
 
== Classification  ==
 
There is no established classification system for Balantis. Based on the etiologies, Balanitis can be classified into:
* Infectious  
* Inflammatory dermatoses  
* Penile carcinoma in situ  


{{familytree/start}}
{{familytree/start}}
{{familytree | | | | | | | | | | | | | | | | | A01 |A01='''Balanitis'''}}  
{{familytree | | | | | | | | | | | | | | | | | A01 |A01='''Balanitis'''}}  
{{familytree | | | | |,|-|-|-|-|-|-|-|-|-|-|-|-|+|-|-|-|-|-|-|-|-|-|-|.| | | }}
{{familytree | | | | |,|-|-|-|-|-|-|-|-|-|-|-|-|+|-|-|-|-|-|-|-|-|-|-|.| | | }}
{{familytree | | | | B01 | | | | | | | | | | | B02 | | | | | | | | | B03 |B01='''Infectious'''|B02='''Inflammatory dermatoses'''|B03='''Premalignant(penile carcinoma in situ)'''}}
{{familytree | | | | B01 | | | | | | | | | | | B02 | | | | | | | | | B03 |B01='''Infectious'''|B02='''Inflammatory dermatoses'''|B03='''Premalignant (penile carcinoma in situ)'''}}
{{familytree | | | | |!| | | | | | | | | | | | |!| | | | | | | | | | |!| | | }}
{{familytree | | | | |!| | | | | | | | | | | | |!| | | | | | | | | | |!| | | }}
{{familytree | | | | |!| | | | | | | | | | | | |!| | | | | | | | | | |!| | | }}
{{familytree | | | | |!| | | | | | | | | | | | |!| | | | | | | | | | |!| | | }}
Line 146: Line 28:
{{familytree/end}}
{{familytree/end}}


==Diagnosis and management==
<br>'''''2008 UK National Guideline on the Management of Balanoposthitis''''' <br>
{| align=center
|-
|
{{familytree/start |summary=Diagnostic and Management approach of balanitis and balanoposthitis}}
{{familytree | | | | | | | | | A01| | | | | | | | | | | | | | A01=Balanitis/balanoposthitis}} 
{{familytree | | | | | | | | | |!| | | | | | |}}
{{familytree | | | | | | | | | B01 | | | | | B01=Take history and examine}}
{{familytree | | | |,|-|-|-|-|-|^|-|-|-|-|-|-|-|-|-|.| | | }}
{{familytree | | | C01 | | | | | | | | | | | | | | C02 | |C01=Perpuce retracts|C02=Perpuce does not retract}}
{{familytree | |,|-|^|-|-|-|-|.| | | | | | |,|-|-|-|^|-|-|.| |}}
{{familytree | D01 | | | | | D02 | | | | | | D03 | | | | D04 |D01=Ulceration present|D02=Erythema,subpreputial discharge|D03=Prepuce scarred|D04=Prepuce swollen}}
{{familytree | |!| | | |,|-|-|^|-|.| | | | | |!| | | | | |!|}}
{{familytree | E01 | | E02 | | | E03 | | | | E04 | | | | E05 |E01=Follow genital ulcer protocol|E02=Fowl smelling|E03=No odour|E04=Refer to surgical opinion|E05=Treat as genital ulcer disease}}
{{familytree | |!| | | |!| | | | |!| | | | | |!| | | | | |!| | | |}}
{{familytree | |!| | | F01 | | | F02 | | | | |!| | | | | |!| | | | |F01=Metronidazole 400 mg bd|F02=Antifungal+1% Hydrocortisone cream apply bd}}
{{familytree | |!| | | |!| | | | |!| | | | | |!| | | | | |!|}}
{{familytree | |`|-|-|-|^|-|-| G01 |-|-|-|-|-|^|-|-|-|-|-|'| | | | | | |G01=Review}}
{{familytree | | | | | | | |,|-|^|-|.| | | | | | | | | | | | | | |}}
{{familytree | | | | | | | H01 | | H02 | | | | | | | | | | | | | | | |H01=If better discharge|H02=If not better 1) Reassess-try alternative pathyway 2) Erythromycin 500 bd 3) Potent steroid cream}}
{{familytree/end}}
|}


== Differential Diagnosis ==
==[[Balanitis differential diagnosis|Differentiating Balanitis from other Diseases]]==
==Synopsis==
{| class="wikitable"
{| class="wikitable"
! colspan="3" |Symptoms
! colspan="4" |Signs
|-
!
!
!Malaise
!Pruritus
!Skin lesions
!Regional lymphadenopathy
!Erythema
!Erythema
!Discharge
!Swelling
!Fowl smelling discharge
!Circinate lesions
!Grouped vesicles present
!Becomes aceto white on application of 5% acetic white
!White patches
!Purplish lesion
!pinpoint redder spots
!Red scaly plaques
!Failure to respond to treatment
|-
|-
|Candida Balanitis
|[[Candidiasis|Candida balanitis]]
|
|
|
|
|
|[[Erythematous]] [[Rash (patient information)|rash]] with soreness and/or [[itch]]
|
|
|
|
|
|
|
|
|
|
|
|-
|-
|Anaerobic Infection
|[[Trichomonas vaginalis]]
|
|
|
|
|
|Superficial erosive [[balanitis]] 
|
|
|
|
|
|
|
|
|
|
|
|-
|-
|Aerobic Infection
|[[Treponema pallidum]]
|
|
|
|
|
|Multiple circinate lesions
|
|
|
|
|
|
|
|
|
|
|
|-
|-
|Trichomonas vaginalis
|[[Herpes simplex]]
|
|
|
|
|
|Grouped [[vesicles]] on [[erythematous]] base
|
|
|
|
|
|
|
|
|
|
|
|-
|-
|Treponema paliidum
|[[Human papillomavirus|Human papilloma virus]]
|
|
|
|
|
|[[Warts]]
|
|
|
|
|
|
|
|
|
|
|
|-
|-
|Herpes simplex
|[[Lichen sclerosus]]
|
|
|
|
|
|White patches on glans
|
|
|
|
|
|
|
|
|
|
|
|-
|-
|Human papilloma virus
|[[Lichen planus]]
|
|
|
|
|
|Purplish lesions on the [[penis]]
|
|
|
|
|
|
|
|
|
|
|
|-
|-
|Lichen sclerosus
|[[Psoriasis]]
|
|
|
|
|
|Red scaly plaques
|
|
|
|
|
|
|
|
|
|
|
|-
|-
|Lichen Planus
|[[Reiter's Syndrome|Circinate]]
|
|
|
|
|
|Greyish white areas on the [[glans]]
|
|
|
|
|
|
|
|
|
|
|
|-
|-
|Psoriasis
|[[Zoon's balanitis]]
|
|
|
|
|
|Well-circumscribed orange-red glazed areas
|
|
|
|
|
|
|
|
|
|
|
|-
|-
|Circinate
|[[Eczema]]
|
|
|
|
|
|Mild non-specific [[erythema]] to wide spread [[edema]] of [[penis]].
|
|
|
|
|
|
|
|
|
|
|
|-
|-
|Zoon's balanitis
|[[Fixed drug eruption]]
|
|
|
|
|
|Well demarcated and [[Erythema|erythematous]] lesions
|
|
|
|
|
|
|
|
|
|
|
|-
|-
|Eczema
|[[Bowen's disease]]
|
|
|
|
|
|Multiple, small, well-demarcated [[Papillomatosis|papillomatous]] [[papules]]
|
|
|
|
|
|
|
|
|
|
|
|-
|-
|Allergic reaction
|[[Bowenoid papulosis]]
|
|
|
|
|
|Single or multiple, sharply demarcated associated with [[Scaling skin|scaling]] and crusting
|
|
|
|
|
|
|
|
|
|
|
|-
|-
|Bowen's disease
|[[Erythroplasia of Queyrat]]
|
|
|
|
|
|Velvety patches and [[plaques]] of [[keratinization]] on [[penis]].
|
|
|
|
|
|
|
|
|
|
|
|-
|Bowenoid papulosis
|
|
|
|
|
|
|
|
|
|
|
|-
|Erythroplasia of Queyrat
|
|
|
|
|
|
|
|
|
|
|
|}
|}
==[[Balanitis epidemiology and demographics|Epidemiology and Demographics]]==
*There are no comprehensive studies studying the [[incidence]] and [[prevalence]] in general population. A recent study has shown that balanitis commonly occurs in around 10% of the patient population visiting the [[STD]] clinic, with [[infectious]] etiology responsible for around 50% of the cases.<ref name="pmid8707315">{{cite journal| author=Edwards S| title=Balanitis and balanoposthitis: a review. | journal=Genitourin Med | year= 1996 | volume= 72 | issue= 3 | pages= 155-9 | pmid=8707315 | doi= | pmc=1195642 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8707315  }}</ref>
*[[Candidiasis|Candida]] is the most common cause being responsible for 30-35% cases with infectious etiology.<ref name="pmid8566986">{{cite journal| author=Dockerty WG, Sonnex C| title=Candidal balano-posthitis: a study of diagnostic methods. | journal=Genitourin Med | year= 1995 | volume= 71 | issue= 6 | pages= 407-9 | pmid=8566986 | doi= | pmc=1196117 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8566986  }}</ref>
==[[Balanitis risk factors|Risk Factors]]==
Pathogen Route of transmission Risk factors Virulence factors
Candidal Balanitis
Sexual transmitted
Opportunistic infection
Diabetes
Immunocompromised conditions
Age>40 yrs
All strains of C. albicans possess a yeast surface mannoprotein. This allows the various strains to adhere to both the exfoliated and epithelial cells.
Other virulence factors  inclu:de proteolytic enzymes, toxins and phospholipase. Proteolytic enzymes destroy the proteins that normally impair fungal invasion
Anaerobic Infection
Sexually transmitted
Extension from peri-rectal area
Oro-genital sex-(saliva as a lubricant during coitus)
.
Tight foreskin
sub-optimal penile hygienic maintenance
Anaerobic gram-negative rods produce various toxins, proteases, and elastase
Aerobic
Infections
Sexually transmitted
Autoinoculation from other sites
Uncircumcised penis
Diabetes
Immunocompromise conditions
Adherence to epithelial cells, biofilm production, surface hydrophobicity, phospholipase C and protease activity
Trichomonas vaginalis Sexually transmitted
Multiple sexual partners
Unprotected sexual activity
Co-existing venereal diseases
Adherence, contact-independent factors, hemolysis and acquisition of host macromolecules have been shown to play a role in the pathogenesis of this infection
Treponema
pallidum
Transmitted via direct contact with the infected lesion (sexual contact) Risk factors include:[8][9][10][11][12][13][14]Multiple sexual partners, prostitution, illicit drug use, unprotected sex
men who have sex with men, residence in highly prevalent areas, HIV infection, presence of other STIs, previous history of STIs, intravenous drug use, health care professionals who are predisposed to occupational risk, and low socioeconomic status
Treponema Pallidum uses fibronectin molecules to attach to the endothelial surface of the vessels in organs resulting in inflammation and obliteration of the small blood vessels causing vasculitis (endarteritis obliterans)
Herpes simplex Often transmitted sexually or direct contact with droplet or infected secretions entering thorough skin or mucous membranes
Multiple sexual partners
Low socio-economic status
Inhibition of MHC Class I
Impairing function of dendritric cells
Human papilloma virus Usually transmitted via sexual route to the human host Risk factors responsible for sexual transmission of HPV include:
Number of sex partners[15][16], acqusition of new partner[15]
, having non monogamous sex partner[17][18], starting sexual activity in young age[17], vaginal delivery and multiple deliveries[19], age over 40 for women[20], history of Chlamydia infection[21], and long term OCP use[22]
Linked to epithelial differentiation and maturation of host keratinocytes, with transcription of specific gene products at every level.
==[[Balanitis screening|Screening]]==
==[[Balanitis natural history, complications and prognosis|Natural History, Complications and Prognosis]]==
== Diagnosis ==
[[Balanitis diagnostic criteria| Diagnostic Criteria]] | [[Balanitis history and symptoms| History and Symptoms]] | [[Balanitis physical examination | Physical Examination]] | [[Balanitis laboratory findings | Laboratory Findings]] | [[Balanitis chest x ray|X-ray]]|[[CT-Scan]]| [[MRI]]|  [[Balanitis other diagnostic studies|Other Diagnostic Studies]]
==Treatment==
[[Balanitis medical therapy|Medical Therapy]] | [[Balanitis primary prevention|Primary Prevention]]  | [[Balanitis secondary prevention|Secondary Prevention]] | [[Balanitis cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Balanitis future or investigational therapies|Future or Investigational Therapies]]


== References ==
== References ==

Revision as of 16:44, 1 March 2017

Balanitis Microchapters

Patient Information

Overview

Classification

Infectious balanitis
Non-infectious balanitits
Zoon's balanitis
Balanitis xerotica obliterans

Causes

Differential Diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vishal Devarkonda, M.B.B.S[2] Synonyms and keywords: Balanoposthitis

Overview

Overview

Balanitis is inflammation of glans penis. When inflammation involves the foreskin and prepuce, it is termed as balanoposthitis. Based on the etiology, balanitis can be mainly categorized into infectious, inflammatory dermatoses, and penile carcinoma in situ. Patients with balanitis may present with asymptomatic or symptomatic lesions with itch or pain in the genital region. Risk factors, pathogenesis, clinical presentation, diagnosis and management varies depending on etiology.

Historical Perspective

Balanitis is an ancient disease,The term Balanitis is derived from a Greek term balanos or acorn.

Pathophysiology

Causes

There is no established classification system for Balantis. Based on the etiologies, Balanitis can be classified into:[1]

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balanitis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Infectious
 
 
 
 
 
 
 
 
 
 
Inflammatory dermatoses
 
 
 
 
 
 
 
 
Premalignant (penile carcinoma in situ)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Candida (albicans, krusei)
Streptococci
Anaerobes
Staphylococci
Trichomonas vaginalis
Herpes simplex virus
Human papillomavirus
Mycoplasma genitalium
 
 
 
 
 
 
 
 
 
 
Lichen sclerosus
Lichen planus
Psoriasis
Circinate balanitis
Zoon's balanitis
Eczema
Allergic reactions
 
 
 
 
 
 
 
 
Bowen's disease
Bowenoid papulosis
Erythroplasia of Queyrat


Differentiating Balanitis from other Diseases

Synopsis

Symptoms Signs
Malaise Pruritus Skin lesions Regional lymphadenopathy Erythema Swelling
Candida balanitis Erythematous rash with soreness and/or itch
Trichomonas vaginalis Superficial erosive balanitis 
Treponema pallidum Multiple circinate lesions
Herpes simplex Grouped vesicles on erythematous base
Human papilloma virus Warts
Lichen sclerosus White patches on glans
Lichen planus Purplish lesions on the penis
Psoriasis Red scaly plaques
Circinate Greyish white areas on the glans
Zoon's balanitis Well-circumscribed orange-red glazed areas
Eczema Mild non-specific erythema to wide spread edema of penis.
Fixed drug eruption Well demarcated and erythematous lesions
Bowen's disease Multiple, small, well-demarcated papillomatous papules
Bowenoid papulosis Single or multiple, sharply demarcated associated with scaling and crusting
Erythroplasia of Queyrat Velvety patches and plaques of keratinization on penis.


Epidemiology and Demographics

  • There are no comprehensive studies studying the incidence and prevalence in general population. A recent study has shown that balanitis commonly occurs in around 10% of the patient population visiting the STD clinic, with infectious etiology responsible for around 50% of the cases.[2]
  • Candida is the most common cause being responsible for 30-35% cases with infectious etiology.[3]

Risk Factors

Pathogen Route of transmission Risk factors Virulence factors Candidal Balanitis Sexual transmitted Opportunistic infection Diabetes Immunocompromised conditions Age>40 yrs All strains of C. albicans possess a yeast surface mannoprotein. This allows the various strains to adhere to both the exfoliated and epithelial cells. Other virulence factors inclu:de proteolytic enzymes, toxins and phospholipase. Proteolytic enzymes destroy the proteins that normally impair fungal invasion Anaerobic Infection Sexually transmitted Extension from peri-rectal area Oro-genital sex-(saliva as a lubricant during coitus) . Tight foreskin sub-optimal penile hygienic maintenance Anaerobic gram-negative rods produce various toxins, proteases, and elastase Aerobic Infections Sexually transmitted Autoinoculation from other sites Uncircumcised penis Diabetes Immunocompromise conditions Adherence to epithelial cells, biofilm production, surface hydrophobicity, phospholipase C and protease activity Trichomonas vaginalis Sexually transmitted Multiple sexual partners Unprotected sexual activity Co-existing venereal diseases Adherence, contact-independent factors, hemolysis and acquisition of host macromolecules have been shown to play a role in the pathogenesis of this infection Treponema pallidum Transmitted via direct contact with the infected lesion (sexual contact) Risk factors include:[8][9][10][11][12][13][14]Multiple sexual partners, prostitution, illicit drug use, unprotected sex men who have sex with men, residence in highly prevalent areas, HIV infection, presence of other STIs, previous history of STIs, intravenous drug use, health care professionals who are predisposed to occupational risk, and low socioeconomic status Treponema Pallidum uses fibronectin molecules to attach to the endothelial surface of the vessels in organs resulting in inflammation and obliteration of the small blood vessels causing vasculitis (endarteritis obliterans) Herpes simplex Often transmitted sexually or direct contact with droplet or infected secretions entering thorough skin or mucous membranes Multiple sexual partners Low socio-economic status Inhibition of MHC Class I Impairing function of dendritric cells Human papilloma virus Usually transmitted via sexual route to the human host Risk factors responsible for sexual transmission of HPV include: Number of sex partners[15][16], acqusition of new partner[15] , having non monogamous sex partner[17][18], starting sexual activity in young age[17], vaginal delivery and multiple deliveries[19], age over 40 for women[20], history of Chlamydia infection[21], and long term OCP use[22] Linked to epithelial differentiation and maturation of host keratinocytes, with transcription of specific gene products at every level.

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria | History and Symptoms | Physical Examination | Laboratory Findings | X-ray|CT-Scan| MRI| Other Diagnostic Studies

Treatment

Medical Therapy | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

References

  1. Edwards SK, Bunker CB, Ziller F, van der Meijden WI (2014). "2013 European guideline for the management of balanoposthitis". Int J STD AIDS. 25 (9): 615–26. doi:10.1177/0956462414533099. PMID 24828553.
  2. Edwards S (1996). "Balanitis and balanoposthitis: a review". Genitourin Med. 72 (3): 155–9. PMC 1195642. PMID 8707315.
  3. Dockerty WG, Sonnex C (1995). "Candidal balano-posthitis: a study of diagnostic methods". Genitourin Med. 71 (6): 407–9. PMC 1196117. PMID 8566986.

Template:WikiDoc Sources